Avalo Therapeutics (AVTX) Expected to Post Earnings on Thursday

Key Points

• Avalo Therapeutics is expected to report Q2 2026 results before the market opens Thursday, August 6. Analysts forecast a loss of $0.66 per share, compared with a $0.98 loss reported for the prior quarter.
• AVTX shares opened at $19.01, down 2.6%, with a 12-month range of $6.51 to $24.27. Analysts maintain a “Moderate Buy” consensus and an average price target of $45.80.
• Insiders sold 77,513 shares worth approximately $1.56 million during the past quarter, while hedge funds and other institutions own 87.06% of the company’s stock.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) is expected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.66) per share for the quarter. Investors are encouraged to explore the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.02. On average, analysts expect Avalo Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Avalo Therapeutics Stock Down 2.6%

Avalo Therapeutics stock opened at $19.01 on Thursday. Avalo Therapeutics has a twelve month low of $6.51 and a twelve month high of $24.27. The company has a market capitalization of $1.01 billion, a P/E ratio of -3.48 and a beta of 0.78. The stock's 50 day moving average is $16.93 and its 200 day moving average is $16.17.

Analyst Ratings Changes

AVTX has been the topic of several analyst reports. Wedbush dropped their target price on Avalo Therapeutics from $40.00 to $34.00 and set an "outperform" rating on the stock in a report on Thursday, May 14th. Leerink Partners began coverage on shares of Avalo Therapeutics in a research note on Monday, July 6th. They issued an "outperform" rating and a $38.00 price target on the stock. Mizuho increased their price objective on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the company an "outperform" rating in a research report on Thursday, May 14th. Piper Sandler reaffirmed an "overweight" rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Finally, Wolfe Research started coverage on shares of Avalo Therapeutics in a research note on Thursday, April 9th. They issued an "outperform" rating and a $48.00 target price on the stock. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Avalo Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $45.80.

Insider Buying and Selling

In related news, insider Paul Varki sold 75,063 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the transaction, the insider owned 3,634 shares in the company, valued at $73,297.78. This represents a 95.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 1,450 shares of the firm's stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the sale, the insider owned 51,776 shares in the company, valued at $931,968. This represents a 2.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 77,513 shares of company stock valued at $1,560,121 over the last quarter. Company insiders own 4.46% of the company's stock.

Institutional Investors Weigh In On Avalo Therapeutics

A number of hedge funds have recently added to or reduced their stakes in AVTX. Squarepoint Ops LLC purchased a new position in shares of Avalo Therapeutics in the 4th quarter worth $742,000. XTX Topco Ltd grew its holdings in shares of Avalo Therapeutics by 190.0% in the fourth quarter. XTX Topco Ltd now owns 40,458 shares of the company's stock worth $735,000 after acquiring an additional 26,508 shares during the period. Two Sigma Investments LP increased its position in Avalo Therapeutics by 282.0% during the third quarter. Two Sigma Investments LP now owns 49,242 shares of the company's stock valued at $626,000 after acquiring an additional 36,353 shares during the last quarter. ExodusPoint Capital Management LP purchased a new stake in Avalo Therapeutics during the fourth quarter valued at $586,000. Finally, Geode Capital Management LLC increased its position in Avalo Therapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company's stock valued at $552,000 after acquiring an additional 2,648 shares during the last quarter. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.